Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial

Kurt Huber, David Holmes Jr, Arnoud van't Hof, Gilles Montalescot, Philip Aylward, Amadeo Betriu, Petr Widimsky, Cynthia Westerhout, Christopher Granger, Paul Armstrong

    Research output: Contribution to journalArticle

    58 Citations (Scopus)

    Abstract

    Aims Controversy exists regarding the early use of glycoprotein IIb/IIIa inhibitors (GPIs) in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial provides a unique opportunity to examine early vs. late or non-use of GPIs in a large STEMI cohort treated with PCI.Methods and resultsIn the APEX-AMI trial, 3969 of 5707 patients received one of three GPIs at the operator's discretion (abciximab, eptifibatide, tirofiban). Of GPI-treated patients, the median time from symptom onset to GPI administration was 180 min (25th, 75th percentile: 130, 258); 1125 received the agent prior to arriving in the catheterization laboratory [pre-sheath; GPI to sheath insertion: 37 min (16, 66)], whereas 2844 patients were treated after arrival in the catheterization laboratory [in-lab; sheath insertion to GPI: 16 min (10, 27)]. The pre-sheath use of GPIs was associated with a significantly lower hazard of 90-day mortality [adjusted hazard ratio (HR) 0.68, 95 confidence interval (CI) 0.48-0.95, P = 0.025] and of 90-day composite of death/CHF/shock (adjusted HR 0.81, 95 CI 0.65-1.00, P = 0.054). In-hospital severe and moderate bleeding was not related to the use of GPIs. Conclusion This retrospective analysis from a large patient cohort with acute STEMI undergoing PCI suggests that pharmacological pre-treatment of PCI with GPIs, particularly abciximab, was associated with significantly lower occurrence of 90-day clinical outcomes and supports the pre-procedural administration of GPIs in this clinical setting.Clinical trial registration information: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00091637.

    Original languageEnglish
    Pages (from-to)1708-1716
    Number of pages9
    JournalEuropean Heart Journal
    Volume31
    Issue number14
    DOIs
    Publication statusPublished - 2010

    Fingerprint Dive into the research topics of 'Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial'. Together they form a unique fingerprint.

  • Cite this

    Huber, K., Holmes Jr, D., van't Hof, A., Montalescot, G., Aylward, P., Betriu, A., Widimsky, P., Westerhout, C., Granger, C., & Armstrong, P. (2010). Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. European Heart Journal, 31(14), 1708-1716. https://doi.org/10.1093/eurheartj/ehq143